Citadel Advisors
IKT icon

Citadel Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Citadel Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.85M Sell
1,102,585
-141,045
-11% -$250K ﹤0.01% 6239
2025
Q4 		$2.55M Buy
1,243,630
+1,171,960
+1,635% +$1.86M ﹤0.01% 5477
2025
Q3 		$116K Buy
+71,670
New +$124K ﹤0.01% 11736
2024
Q3 		– Sell
-37,895
Closed -$49.6K – 14693
2024
Q2 		$49.6K Buy
+37,895
New +$65.3K ﹤0.01% 11764
2022
Q4 		– Sell
-4,019
Closed -$22K – 15145
2022
Q3 		$22K Buy
+4,019
New +$21.1K ﹤0.01% 12036
2021
Q2 		– Sell
-2,976
Closed -$107K – 14012
2021
Q1 		$107K Buy
+2,976
New +$120K ﹤0.01% 12420

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's IKT Position: Q1 2026 in Review

Citadel Advisors reduced its Inhibikase Therapeutics (IKT) stake by 11% in Q1 2026, selling an estimated $250K and leaving 1,102,585 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #6239.

Citadel Advisors first reported a position in IKT in Q1 2021 and has held it in 6 quarters since. The position peaked at $2.55M in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Citadel Advisors held 1,102,585 shares of Inhibikase Therapeutics worth $1.85M as of Q1 2026.
  • Citadel Advisors sold 141,045 Inhibikase Therapeutics shares in Q1 2026, an estimated $250K.
  • Inhibikase Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6239 holding.
  • Citadel Advisors first reported a position in Inhibikase Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Citadel Advisors's Inhibikase Therapeutics position peaked at $2.55M in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.